Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Complete Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion
Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients
with Relapsed/Refractory Multiple Myeloma
Trial Phase: I
Investigator: Andrew Cowan, MD
An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma
Keywords:
- Multiple Myeloma (MM)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Andrew Cowan, MD
RG1121006
NCT04184050
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion
Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients
with Relapsed/Refractory Multiple Myeloma
Multiple Myeloma (MM)